Furthermore, the knockdown of IRF7 and 3—transcription factors of TRAIL and Noxa, respectively [100, 101]—also suppressed the HVJ-E sensitivity of prostate cancer cells, suggesting that RIG-I/MAVS signaling regulates the expression of TRAIL and Noxa via IRF7 and 3 in cancer cells. This evidence concerns the gene IRF7 and prostate carcinoma.